Cubist Systematic Strategies LLC Sells 25,043 Shares of QIAGEN N.V. $QGEN

Cubist Systematic Strategies LLC reduced its holdings in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 35.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,385 shares of the company's stock after selling 25,043 shares during the period. Cubist Systematic Strategies LLC's holdings in QIAGEN were worth $1,862,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of QIAGEN in the 4th quarter valued at about $202,000. GAMMA Investing LLC lifted its position in shares of QIAGEN by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after buying an additional 1,425 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of QIAGEN by 23.2% during the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company's stock worth $551,000 after buying an additional 2,620 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in shares of QIAGEN by 30.2% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock worth $396,000 after buying an additional 2,290 shares in the last quarter. Finally, Federated Hermes Inc. bought a new position in shares of QIAGEN during the 1st quarter worth approximately $150,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

QIAGEN Price Performance

Shares of QGEN traded down $0.50 during mid-day trading on Tuesday, reaching $47.08. 903,884 shares of the stock traded hands, compared to its average volume of 1,318,712. The firm has a fifty day moving average price of $48.62 and a 200 day moving average price of $44.50. The company has a market cap of $10.47 billion, a price-to-earnings ratio of 27.82, a price-to-earnings-growth ratio of 2.51 and a beta of 0.64. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The business's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts predict that QIAGEN N.V. will post 2.26 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on QGEN. Bank of America raised their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. UBS Group raised their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Barclays began coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Finally, Cowen reiterated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $49.69.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.